NASDAQ:CALA

Calithera Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy CALA

*Your capital is at risk

$0.0002

+0 (+0%)

At Close: Jun 03, 2026

Calithera Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 10.85M and sold 6.41M CALA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	10.85M shares
● Sell	6.41M shares
57% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Orford Keith Director	Director	40 000 Value: $17.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Kuriakose Emil Chief Medical Officer	Officer	215 000 Value: $94.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Kuriakose Emil Chief Medical Officer	Officer	215 000 Value: $94.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Orford Keith Director	Director	40 000 Value: $17.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Molineaux Christopher Sr. Vp, Development	Officer	165 000 Value: $72.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Parlati Francesco Sr. Vp, Research	Officer	165 000 Value: $72.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Sjogren Eric Sr. Vp, Drug Discovery	Officer	165 000 Value: $72.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Ray Sumita See Remarks	Officer	165 000 Value: $72.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Wong Stephanie See Remarks	Officer	215 000 Value: $94.6K
Jan 25, 2022 Buy	Employee Stock Option (Right to Buy) A-Award	Molineaux Susan President & CEO	CEO / President	597 475 Value: $262.9K
Jan 21, 2022 Sell	Common Stock F-InKind	Parlati Francesco Sr. Vp, Research	Officer	4 794 Value: $2K
Jan 21, 2022 Sell	Common Stock F-InKind	Wong Stephanie See Remarks	Officer	5 586 Value: $3K
Jan 21, 2022 Sell	Common Stock F-InKind	Sjogren Eric Sr. Vp, Drug Discovery	Officer	4 794 Value: $2K
Jan 21, 2022 Sell	Common Stock F-InKind	Kuriakose Emil Chief Medical Officer	Officer	666 Value: $327
Jan 21, 2022 Sell	Common Stock F-InKind	Kuriakose Emil Chief Medical Officer	Officer	666 Value: $327
Jan 21, 2022 Sell	Common Stock F-InKind	Sjogren Eric Sr. Vp, Drug Discovery	Officer	4 794 Value: $2K
Jan 21, 2022 Sell	Common Stock F-InKind	Wong Stephanie See Remarks	Officer	5 586 Value: $3K
Jan 21, 2022 Sell	Common Stock F-InKind	Parlati Francesco Sr. Vp, Research	Officer	4 794 Value: $2K
Jan 04, 2022 Sell	Common Stock F-InKind	Parlati Francesco Sr. Vp, Research	Officer	18 077 Value: $11.9K
Jan 04, 2022 Sell	Common Stock F-InKind	Kuriakose Emil Chief Medical Officer	Officer	3 855 Value: $3K
Jan 04, 2022 Sell	Common Stock F-InKind	Sjogren Eric Sr. Vp, Drug Discovery	Officer	18 077 Value: $11.9K
Jan 04, 2022 Sell	Common Stock F-InKind	Wong Stephanie See Remarks	Officer	18 077 Value: $11.9K
Jan 04, 2022 Sell	Common Stock F-InKind	Wong Stephanie See Remarks	Officer	18 077 Value: $11.9K
Jan 04, 2022 Sell	Common Stock F-InKind	Sjogren Eric Sr. Vp, Drug Discovery	Officer	18 077 Value: $11.9K
Jan 04, 2022 Sell	Common Stock F-InKind	Kuriakose Emil Chief Medical Officer	Officer	3 855 Value: $3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CALITHERA BIOSCIENCES

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas...

Read Full Profile Here